Is Apellis Pharmaceuticals Stock a Good Investment?
Apellis Pharmaceuticals Investment Advice | APLS |
- Examine Apellis Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Apellis Pharmaceuticals' leadership team and their track record. Good management can help Apellis Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Apellis Pharmaceuticals' business and its evolving consumer preferences.
- Compare Apellis Pharmaceuticals' performance and market position to its competitors. Analyze how Apellis Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Apellis Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Apellis Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Apellis Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Apellis Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Apellis Pharmaceuticals Stock
Researching Apellis Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 3.43. Apellis Pharmaceuticals had not issued any dividends in recent years.
To determine if Apellis Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Apellis Pharmaceuticals' research are outlined below:
| Apellis Pharmaceuticals generated a negative expected return over the last 90 days | |
| Apellis Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 396.59 M. Net Loss for the year was (528.63 M) with profit before overhead, payroll, taxes, and interest of 69.79 M. | |
| Apellis Pharmaceuticals currently holds about 852.8 M in cash with (594.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.76. | |
| Apellis Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from aol.com: APLS budget cut nine percent despite recommended policy changes |
Apellis Pharmaceuticals Quarterly Accounts Payable |
|
Apellis Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Apellis Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apellis Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Apellis Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2018-04-30 | 2018-03-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2018-03-19 | 2017-12-31 | -0.48 | -0.6 | -0.12 | 25 | ||
2018-07-31 | 2018-06-30 | -0.47 | -0.61 | -0.14 | 29 | ||
2019-05-07 | 2019-03-31 | -0.67 | -0.87 | -0.2 | 29 | ||
2020-11-02 | 2020-09-30 | -1.58 | -1.79 | -0.21 | 13 | ||
2020-07-30 | 2020-06-30 | -1.34 | -1.57 | -0.23 | 17 | ||
2023-07-31 | 2023-06-30 | -1.32 | -1.02 | 0.3 | 22 |
Know Apellis Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2024-03-31 | 2.5 M | Fmr Inc | 2023-12-31 | 2.1 M | Assenagon Asset Management Sa | 2024-03-31 | 2 M | Boxer Capital Llc | 2024-03-31 | 1.7 M | Geode Capital Management, Llc | 2023-12-31 | 1.6 M | Artal Group S A | 2023-12-31 | 1.4 M | Orbimed Advisors, Llc | 2024-03-31 | 1.3 M | Pictet Asset Manangement Sa | 2024-03-31 | 1.1 M | Polar Capital Holdings Plc | 2024-03-31 | 1.1 M | Wellington Management Company Llp | 2023-12-31 | 16.4 M | Ecor1 Capital, Llc | 2024-03-31 | 11.4 M |
Apellis Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.76 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apellis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Apellis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Apellis Pharmaceuticals' profitablity analysis
Apellis Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Apellis Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Apellis Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Apellis Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Apellis Pharmaceuticals' profitability requires more research than a typical breakdown of Apellis Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.67) | (0.70) | |
| Return On Capital Employed | (0.96) | (1.00) | |
| Return On Assets | (0.67) | (0.70) | |
| Return On Equity | (2.72) | (2.85) |
Determining Apellis Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Apellis Pharmaceuticals is a good buy. For example, gross profit margin measures Apellis Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Apellis Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Apellis Pharmaceuticals' official financial statements usually reflect Apellis Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Apellis Pharmaceuticals. For example, before you start analyzing numbers published by Apellis accountants, it's critical to develop an understanding of what Apellis Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Apellis Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Apellis Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Apellis Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Apellis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Apellis Pharmaceuticals' management manipulating its earnings.
Evaluate Apellis Pharmaceuticals' management efficiency
Apellis Pharmaceuticals has return on total asset (ROA) of (0.279) % which means that it has lost $0.279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2294) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.64 | 1.95 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 1.64 | 1.95 | |
| Enterprise Value Over EBITDA | (13.31) | (13.98) | |
| Price Book Value Ratio | 36.52 | 19.30 | |
| Enterprise Value Multiple | (13.31) | (13.98) | |
| Price Fair Value | 36.52 | 19.30 | |
| Enterprise Value | 1.5 B | 1.6 B |
The analysis of Apellis Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Apellis Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Apellis Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.965 |
Basic technical analysis of Apellis Stock
As of the 1st of June, Apellis Pharmaceuticals shows the risk adjusted performance of (0.12), and Mean Deviation of 2.58. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate thirteen technical drivers for Apellis Pharmaceuticals, which can be compared to its peers. Please confirm Apellis Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 39.25 per share. Given that Apellis Pharmaceuticals has information ratio of (0.22), we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.Apellis Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apellis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apellis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apellis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Apellis Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Apellis Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.57) | |||
| Mean Deviation | 2.58 | |||
| Coefficient Of Variation | (486.94) | |||
| Standard Deviation | 3.33 | |||
| Variance | 11.07 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (0.58) | |||
| Maximum Drawdown | 16.31 | |||
| Value At Risk | (7.31) | |||
| Potential Upside | 4.03 | |||
| Skewness | (0.67) | |||
| Kurtosis | 0.4902 |
| Risk Adjusted Performance | (0.12) | |||
| Market Risk Adjusted Performance | (0.57) | |||
| Mean Deviation | 2.58 | |||
| Coefficient Of Variation | (486.94) | |||
| Standard Deviation | 3.33 | |||
| Variance | 11.07 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.88) | |||
| Treynor Ratio | (0.58) | |||
| Maximum Drawdown | 16.31 | |||
| Value At Risk | (7.31) | |||
| Potential Upside | 4.03 | |||
| Skewness | (0.67) | |||
| Kurtosis | 0.4902 |
Consider Apellis Pharmaceuticals' intraday indicators
Apellis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Apellis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 112194.0 | |||
| Daily Balance Of Power | (0.66) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 39.49 | |||
| Day Typical Price | 39.41 | |||
| Price Action Indicator | (0.99) | |||
| Period Momentum Indicator | (1.50) |
Apellis Pharmaceuticals Corporate Filings
F4 | 21st of May 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 14th of May 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify |
Apellis Stock media impact
Far too much social signal, news, headlines, and media speculation about Apellis Pharmaceuticals that are available to investors today. That information is available publicly through Apellis media outlets and privately through word of mouth or via Apellis internal channels. However, regardless of the origin, that massive amount of Apellis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Apellis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Apellis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Apellis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Apellis Pharmaceuticals alpha.
Apellis Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Apellis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Apellis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Apellis Pharmaceuticals.
Apellis Pharmaceuticals Maximum Pain Price across 2024-06-21 Option Contracts
Apellis Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Apellis Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Apellis Pharmaceuticals' options.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Apellis Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Bond Analysis Now
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. |
| All Next | Launch Module |
Apellis Pharmaceuticals Corporate Management
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James CPA | Corporate VP | Profile | |
| Cedric MD | President, CoFounder | Profile | |
| Adam Townsend | Chief Commercial Officer | Profile | |
| Karen Lewis | Chief Officer | Profile | |
| Nur Nicholson | Chief Officer | Profile |
How to buy Apellis Stock?
To provide specific investment advice or recommendations on Apellis Pharmaceuticals stock, we recommend investors consider the following general factors when evaluating Apellis Pharmaceuticals. This will help you to make an informed decision on whether to include Apellis Pharmaceuticals in one of your diversified portfolios:- Examine Apellis Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Apellis Pharmaceuticals' leadership team and their track record. Good management can help Apellis Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Apellis Pharmaceuticals' business and its evolving consumer preferences.
- Compare Apellis Pharmaceuticals' performance and market position to its competitors. Analyze how Apellis Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Apellis Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Apellis Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Apellis Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Apellis Pharmaceuticals is a good investment.
Already Invested in Apellis Pharmaceuticals?
The danger of trading Apellis Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apellis Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apellis Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apellis Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Apellis Pharmaceuticals is a strong investment it is important to analyze Apellis Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apellis Pharmaceuticals' future performance. For an informed investment choice regarding Apellis Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Apellis Stock analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.43) | Revenue Per Share 4.333 | Quarterly Revenue Growth 2.843 | Return On Assets (0.28) | Return On Equity (1.23) |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Apellis Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.